- Home
- JSPR vs CMPS Comparison
JSPR vs CMPS Comparison
Compare JSPR & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- CMPS
- Stock Information
- Founded
- JSPR 2018
- CMPS 2020
- Country
- JSPR United States
- CMPS United Kingdom
- Employees
- JSPR N/A
- CMPS 186
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- JSPR Health Care
- CMPS Health Care
- Exchange
- JSPR Nasdaq
- CMPS Nasdaq
- Market Cap
- JSPR 342.2M
- CMPS 280.2M
- IPO Year
- JSPR N/A
- CMPS 2020
- Fundamental
- Price
- JSPR $22.99
- CMPS $4.31
- Analyst Decision
- JSPR Strong Buy
- CMPS Strong Buy
- Analyst Count
- JSPR 10
- CMPS 7
- Target Price
- JSPR $74.86
- CMPS $30.67
- AVG Volume (30 Days)
- JSPR 210.0K
- CMPS 972.1K
- Earning Date
- JSPR 11-07-2024
- CMPS 10-31-2024
- Dividend Yield
- JSPR N/A
- CMPS N/A
- EPS Growth
- JSPR N/A
- CMPS N/A
- EPS
- JSPR N/A
- CMPS N/A
- Revenue
- JSPR N/A
- CMPS N/A
- Revenue This Year
- JSPR N/A
- CMPS N/A
- Revenue Next Year
- JSPR N/A
- CMPS N/A
- P/E Ratio
- JSPR N/A
- CMPS N/A
- Revenue Growth
- JSPR N/A
- CMPS N/A
- 52 Week Low
- JSPR $4.00
- CMPS $4.00
- 52 Week High
- JSPR $31.01
- CMPS $12.75
- Technical
- Relative Strength Index (RSI)
- JSPR 53.28
- CMPS 34.32
- Support Level
- JSPR $20.73
- CMPS $4.00
- Resistance Level
- JSPR $26.05
- CMPS $4.66
- Average True Range (ATR)
- JSPR 1.58
- CMPS 0.25
- MACD
- JSPR -0.08
- CMPS 0.00
- Stochastic Oscillator
- JSPR 51.88
- CMPS 20.26
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.